Meeting
2011 ASCO Annual Meeting
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919).
Authors
W. Parulekar
NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada
W. Parulekar , J. W. Chapman , S. Aparicio , Y. Murray , F. M. Boyle , A. Di Leo , B. Kaufman , C. Levy , A. Manikhas , M. Martin , K. I. Pritchard , L. S. Schwartzberg , M. J. Burnell , S. Dent , S. Ellard , K. S. Tonkin , T. J. Whelan , J. Lemieux , L. Bordeleau , K. A. Gelmon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
HER2+
Clinical Trial Registration Number
NCT00667251
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS108)
Abstract #
TPS108
Poster Bd #
37B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
First Author: Hiroshige Yoshioka
Poster
2020 ASCO Virtual Scientific Program
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).
First Author: Sudpreeda Chainitikun
Poster
2014 ASCO Annual Meeting
Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic breast cancer (SELECT BC).
First Author: Fumikata Hara
Poster
2013 ASCO Annual Meeting
Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.
First Author: Stefan Michiels